Clinical trialNCT07053436RecruitingPhase 2Interventional

Horizon Two: HR NDMM (MMRC-100)

SponsorMultiple Myeloma Research ConsortiumEnrollment300High Risk Newly Diagnosed Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Multiple Myeloma Research Consortium (MMRC) Horizon Two trial is a master protocol, multi-center, phase II randomized adaptive platform trial designed to efficiently evaluate multiple investigational therapies in high-risk newly diagnosed multiple myeloma patients using an integrated and patient-centric clinical research platform that enables longitudinal learning and sharing of knowledge and investigates multiple novel therapeutic strategies within one trial platform.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Hearn Jay Cho, MD, PhD
Multiple Myeloma Research Foundation
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Emory University
Atlanta, Georgia, United States
Recruiting
Uchicago Medicine
Chicago, Illinois, United States
Recruiting
Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Recruiting
Washington University Medical Center
St Louis, Missouri, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Unc
Chapel Hill, North Carolina, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bispecific Monoclonal Antibody and Triplet TherapyMonoclonal Antibody with Stem Cell Transplant

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2026
Primary completion: 1 Oct 2035
Completion: 12 Oct 2035
Last update posted: 10 Jun 2026
Registered enrollment: 300
Registry id: NCT07053436

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.